RecruitingPHASE1, PHASE2NCT03972657
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Studying Clear cell renal carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Regeneron Pharmaceuticals
- Principal Investigator
- Clinical Trials ManagementRegeneron Pharmaceuticals
- Intervention
- REGN5678(drug)
- Enrollment
- 345 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2027
Study locations (21)
- Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
- Mayo Clinic, Phoenix, Arizona, United States
- University of Arizona, Tucson, Arizona, United States
- John Wayne Cancer Institute (JWCI), Santa Monica, California, United States
- Sarah Cannon Research Institute (SCRI), Denver, Colorado, United States
- Yale University Hospital, New Haven, Connecticut, United States
- Mayo Clinic Jacksonville, Jacksonville, Florida, United States
- Moffitt Cancer Center - McKinley Drive, Tampa, Florida, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Mayo Clinic, Rochester, Minnesota, United States
- NYU Langone Health Perlmutter Cancer Center, New York, New York, United States
- Icahn School of Medicine at Mount Sinai, New York, New York, United States
- Columbia University - The Trustees of Columbia University in the City of New York, New York, New York, United States
- Montefiore Medical Center, New York, New York, United States
- University of Rochester Medical Center (URMC) - Wilmot Cancer Institute (WCI) (James P. Wilmot Cancer Center) - Rochester, Rochester, New York, United States
- +6 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03972657 on ClinicalTrials.govOther trials for Clear cell renal carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07128680Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell CancerCity of Hope Medical Center
- RECRUITINGPHASE2NCT06863311Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCCKarie Runcie
- RECRUITINGPHASE2NCT07397611Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCCDana-Farber Cancer Institute
- RECRUITINGPHASE2NCT07469683An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell CarcinomaYonsei University
- RECRUITINGPHASE2NCT07188896A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)Brian Rini
- RECRUITINGPHASE1, PHASE2NCT07227415A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell CancerPfizer
- RECRUITINGPHASE1, PHASE2NCT07551349Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell CarcinomaBeijing Biotech
- RECRUITINGPHASE2NCT07223541Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell CarcinomaUniversity of Oklahoma